Neoadjuvant Nivolumab Checks Lung Cancer [News in Brief]

In pilot study, PD-1 inhibitor produced major pathologic responses in many patients with early-stage NSCLC.

from Cancer via ola Kala on Inoreader https://ift.tt/2HEwUBN
via IFTTT